Eli Lilly Shares Under Pressure Following Strategic Price Cuts
07.12.2025 - 04:02:04 | boerse-global.de
Investor sentiment toward Eli Lilly turned cautious last week, with the pharmaceutical giant’s stock declining approximately 4.5% over a five-day period. The move followed the company’s announcement of significant price reductions for its weight-loss medication, Zepbound, raising questions about the impact on future profitability in a key growth segment.
In early December, Eli Lilly unveiled new pricing for single-dose vials of Zepbound through its direct-to-consumer platform, LillyDirect. The adjustments represent a substantial decrease across all dosage strengths.
The company framed the decision as a move to improve patient access. Ilya Yuffa, Executive Vice President of Lilly USA, stated that significant cost and reimbursement barriers continue to Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt kostenlos anmelden
Jetzt abonnieren.
